Home Johnson & Johnson

Johnson & Johnson

DePuy Synthes Expands Comprehensive Offering to Treat Degenerative Spine Disease with Launch of 3D Printed Implant Portfolio for Spine Surgery

The innovative portfolio, which includes 3D printed titanium interbody implants for spinal fusion surgery is designed to mimic natural bone and help facilitate spinal fusion.

VISTASEAL Open and Laparoscopic Dual Applicator Devices Designed to Deliver Biologics that Addresses Surgical Bleeding

Ethicon has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its VISTASEAL open and laparoscopic Dual Applicators (35 cm and 45 cm), three next generation airless spray devices that combine biologics with device technology to address mild to moderate surgical bleeding.  

Initial Results from First In-Human Study of Novel High Power-Short Duration Catheter

Johnson & Johnson Medical Devices Companies* today announced that Biosense Webster, Inc.’s QDOT MICRO, a novel catheter that facilitates high power-short duration radiofrequency ablation, demonstrated safety and efficacy in achieving pulmonary vein isolation in patients with symptomatic drug-refractory paroxysmal atrial fibrillation in QDOT-FAST, the first in-human multicenter study of the device. Procedure and fluoroscopy times were also reported to be shorter than ablation with conventional catheters. Reducing use of fluoroscopy alleviates the burden of lead for physicians and staff, and reduces exposure to radiation for patients.

NEUWAVE Microwave Ablation System: Ethicon Launches Global Registry to Collect Real-World Data

3/25/19: Real-world data will be collected from up to 30 centers throughout the world on the technical aspects of the procedure including ablation time under varying liver tissue and lesion conditions.

Johnson & Johnson Announces Agreement to Acquire Auris Health, Inc.

2/13/19: Johnson & Johnson entered into a definitive agreement to acquire Auris Health, Inc. for approximately $3.4 billion in cash. Auris Health is a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. This acquisition will accelerate Johnson & Johnson's entry into robotics with potential for growth and expansion into other interventional applications.

First Atrial Fibrillation Patient Treated in Biosense Webster U.S. IDE Study

2/4/19: The first AF patient was treated at NYU Langone Health’s Heart Rhythm Center in New York City, one of up to 30 centers participating in the study that will enroll up to 185 patients throughout the U.S.

First Patient Treated in Biosense Webster U.S. IDE Study Evaluating Next Generation Balloon Ablation Catheter for Treating Atrial Fibrillation

12/4/18: The study will evaluate the safety and effectiveness of HELIOSTAR Multi-electrode Radiofrequency (RF) Balloon Ablation Catheter in treating symptomatic drug refractory recurrent paroxysmal (intermittent) atrial fibrillation (AF). Up to 640 patients will be enrolled in as many as 40 clinical sites worldwide.

Johnson & Johnson Announces Binding Offer from Platinum Equity to Acquire LifeScan, Inc.

3/16/18: Johnson & Johnson announced that it has received a binding offer from Platinum Equity, a leading private investment firm, to acquire its LifeScan business for approximately $2.1 billion, subject to customary adjustments. LifeScan, Inc. is a leader in blood glucose monitoring products with 2017 net revenue of approximately $1.5 billion.